Effect of Suboccipital Release in Patients With Fibromyalgia Syndrome (NCT06879743) | Clinical Trial Compass
RecruitingNot Applicable
Effect of Suboccipital Release in Patients With Fibromyalgia Syndrome
Egypt40 participantsStarted 2024-02-01
Plain-language summary
This study was designed to examine the efficacy of suboccipital release in Patients With FMS and to provide preliminary evidence regarding its effects on pain and QOL by objectively measuring Cortisol level in FMS patien
Who can participate
Age range20 Years – 45 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* women between 20-45 years old, (ii) diagnoses according to the 2016
American College of Rheumatology criteria for fibromyalgia \[1\]
* Symptoms have been present at a similar level for at least three months (iii) Absence of other disorders that causes similar symptoms: systemic lupus erethromatosis (SLE), rheumatoid arthritis (RA) and Lyme disease based on laboratory investigations (erythrocyte sedimentation rate (ESR), Anti anti-cyclic citrullinated peptide (Anti CCP), antinuclear antibody (ANA) and Rheumatoid factor(RF)).
* Exclusion Criteria:
* any medical, neurological, or psychiatric illness, use of strong opioids or other painkillers except paracetamol and/or ibuprofen, benzodiazepine, illicit drug or alcohol use, recent use of cannabis, pregnancy, breast feeding, and the presence of pain syndromes other than FM. Presence of other autoimmune disorders e.g.: rheumatoid arthritis and systemic lupus erethromatosus
What they're measuring
1
Cortisol level
Timeframe: Six weeks after begining of intervention